In the past week, LLY stock has gone down by -3.79%, with a monthly gain of 6.57% and a quarterly surge of 27.98%. The volatility ratio for the week is 2.29%, and the volatility levels for the last 30 days are 1.91% for Eli Lilly and Company The simple moving average for the past 20 days is 1.32% for LLY’s stock, with a 39.35% simple moving average for the past 200 days.
Is It Worth Investing in Eli Lilly and Company (NYSE: LLY) Right Now?
The price-to-earnings ratio for Eli Lilly and Company (NYSE: LLY) is above average at 79.61x. The 36-month beta value for LLY is also noteworthy at 0.31. There are mixed opinions on the stock, with 19 analysts rating it as a “buy,” 3 rating it as “overweight,” 4 rating it as “hold,” and 1 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price estimated by analysts for LLY is $571.51, which is -$3.29 below than the current price. The public float for LLY is 947.47M, and at present, short sellers hold a 0.59% of that float. The average trading volume of LLY on September 18, 2023 was 2.93M shares.
LLY) stock’s latest price update
Eli Lilly and Company (NYSE: LLY) has seen a decline in its stock price by -0.46 in relation to its previous close of 575.66. However, the company has experienced a -3.79% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2023-09-13 that Eli Lilly’s stock has performed well in the market, boosted by strong fundamental results and the success of Novo Nordisk’s weight loss drug, Wegovy. Wegovy demonstrated a 20% reduction in the risk of heart attack, stroke, or heart-related death in obese or overweight individuals with cardiovascular disease. The success of Wegovy could have positive implications for Eli Lilly’s incretin drugs, tirzepatide and retatrutide, in the field of obesity treatment.
Analysts’ Opinion of LLY
Many brokerage firms have already submitted their reports for LLY stocks, with Jefferies repeating the rating for LLY by listing it as a “Buy.” The predicted price for LLY in the upcoming period, according to Jefferies is $615 based on the research report published on August 09, 2023 of the current year 2023.
LLY Trading at 12.25% from the 50-Day Moving Average
After a stumble in the market that brought LLY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.79% of loss for the given period.
Volatility was left at 1.91%, however, over the last 30 days, the volatility rate increased by 2.29%, as shares surge +4.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.11% upper at present.
During the last 5 trading sessions, LLY fell by -4.27%, which changed the moving average for the period of 200-days by +56.65% in comparison to the 20-day moving average, which settled at $566.74. In addition, Eli Lilly and Company saw 56.63% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LLY starting from Weems Alonzo, who sale 1,148 shares at the price of $590.98 back on Sep 12. After this action, Weems Alonzo now owns 7,760 shares of Eli Lilly and Company, valued at $678,445 using the latest closing price.
LILLY ENDOWMENT INC, the 10% Owner of Eli Lilly and Company, sale 210,000 shares at $571.41 during a trade that took place back on Sep 07, which means that LILLY ENDOWMENT INC is holding 99,983,810 shares at $119,995,275 based on the most recent closing price.
Stock Fundamentals for LLY
Current profitability levels for the company are sitting at:
- +29.01 for the present operating margin
- +76.77 for the gross margin
The net margin for Eli Lilly and Company stands at +21.88. The total capital return value is set at 31.22, while invested capital returns managed to touch 25.12. Equity return is now at value 60.50, with 12.70 for asset returns.
Based on Eli Lilly and Company (LLY), the company’s capital structure generated 152.48 points at debt to equity in total, while total debt to capital is 60.39. Total debt to assets is 32.81, with long-term debt to equity ratio resting at 138.38. Finally, the long-term debt to capital ratio is 54.81.
When we switch over and look at the enterprise to sales, we see a ratio of 18.99, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 3.42 and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.05.
Conclusion
In summary, Eli Lilly and Company (LLY) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
